Quinazoline amine compound as well as preparation method and application thereof
By developing quinazolineamine compounds, SOS1/EGFR dual-target inhibitors for tumor treatment were prepared, and the problem of poor efficacy of SOS1 and EGFR inhibitors in the prior art was solved, effective inhibition of tumors was achieved, and the toxicity risk of combined administration.
Patent Information
- Application Number
- CN202411134200.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-08-19
AI Technical Summary
The existing SOS1 inhibitors and EGFR inhibitors have poor efficacy in tumor treatment, and the combined administration has problems of toxicity, poor compliance and drug interaction, and lacks effective SOS1/EGFR dual-target small molecule inhibitors.
Develop a new quinazoline amine compound and its pharmaceutical salt for the preparation of SOS1/EGFR dual-target inhibitors, prepare the compound through a synthetic route, and conduct in vitro protein level activity tests and cell proliferation inhibitory activity tests to verify Its effect of inhibiting SOS1 and EGFR.
This compound can effectively inhibit SOS1 and EGFR targets, significantly improve the therapeutic effect on tumors, provide a new dual-target inhibitor, solve the problem of poor efficacy of existing single-target drugs, and reduce the combined effect of toxicity risk of drug.
Smart Images

Figure CN119039237A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical chemistry, and specifically relates to a quinazoline amine compound and a preparation method and application thereof. Background Art
[0002] SOS1 (Son of sevenless homologue 1) protein is a guanine nucleotide exchange factor (GEFs) that is widely expressed in humans and is associated with various human cancers and other diseases. In human cells, activated SOS1 can promote the conversion between inactive RAS-GDP and active RAS-GTP, while activated RAS (Rat Sarcoma Virus) can activate multiple downstream signals, such as RAF-MEK-ERK, PI3K-AKT-mTOR and Ral-GDS, to regulate cell survival and proliferation. Inhibition of SOS1 protein can inhibit the activation of RAS protein, thereby inhibiting the occurrence and development of tumors. Research on SOS1 inhibitors is mainly focused on the development of targeted SOS1 orthosteric inhibitors. At present, SOS1 inhibitors are still in the early stages of research and development, and only MRTX0902 and BI1701963 have entered clinical trials.
[0003] Epidermal Growth Factor Receptor (EGFR) is a member of the HER family. EGFR is closely related to tumor proliferation, invasion and metastasis. EGFR dimerizes under the binding of epidermal growth factor (EGF) or transforming growth factor-α (TGFα). Activated EGFR stimulates downstream related pathways, including RAS-RAF-MEK-ERK, PI3K-AKT-mTOR and JAK-STAT pathways, leading to tumor growth. Therefore, targeting EGFR is an effective means of treating tumors. At present, EGFR inhibitors such as gefitinib have been approved for marketing.
[0004] EGFR and SOS1 are two proteins located on the same signaling pathway. Studies have shown that combined inhibition of SOS1 and EGFR has a stronger anti-tumor effect on KRAS mutant tumors. For complex diseases with abnormalities in multiple signaling pathways, combined administration has better anti-tumor efficacy than single-target combined therapy. However, combined administration has problems such as toxicity, poor compliance, and drug-drug interactions. Therefore, it is of great significance to develop new SOS1 / EGFR dual-target small molecule inhibitors with good anti-tumor activity. Summary of the invention
[0005] The purpose of the present invention is to provide a SOS1 / EGFR dual-target compound to solve the problem that the current SOS1 inhibitors and EGFR inhibitors have poor efficacy in tumor treatment.
[0006] The technical solution of the present invention is as follows:
[0007] A quinazoline amine compound as shown in Formula I and a pharmaceutically acceptable salt thereof, the structure of which is as follows:
[0008]
[0009] Ar is selected from Among them, R 1 –R 3 Each is independently selected from hydrogen, deuterium, halogen, methyl, trifluoromethyl, cyano, and amino.
[0010] Preferably, the quinazoline amines and pharmaceutically acceptable salts thereof as shown in Formula I are any of the following compounds:
[0011]
[0012]
[0013] A pharmaceutical composition comprising the compound of claims 1 to 2 and a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or.
[0014] The use of the quinazoline amine compound and its pharmaceutically acceptable salt, and the pharmaceutical composition for preparing SOS1 / EGFR dual-target inhibitor drugs.
[0015] Use of the quinazoline amine compounds and pharmaceutically acceptable salts thereof and the pharmaceutical composition as claimed in claims 1 to 2 in the preparation of drugs for preventing and / or treating tumors.
[0016] Beneficial effects:
[0017] Compared with the prior art, the present invention has the following significant features: the present invention discloses a new compound represented by general formula I, which can effectively inhibit SOS1 and EGFR targets and can be used to prepare drugs for treating cancer or tumor-related diseases; the present invention also discloses a method for preparing the compound of general formula I. DETAILED DESCRIPTION
[0018] In order to better understand the present invention, the present invention is further illustrated by the following examples, but the content of the present invention is not limited to the following examples.
[0019] Example 1
[0020]
[0021] Synthesis route:
[0022]
[0023] Synthesis of Compound I-1
[0024] I-1a (100.0 mg, 0.42 mmol), I-1b (141.5 mg, 0.42 mmol, 1.0 eq) and N,N-diisopropylethylamine (162.9 mg, 1.26 mmol, 3.0 eq) were dissolved in 1.0 mL of DMSO. The reaction solution was stirred at 60 ° C for 12 hours overnight, diluted with water, and extracted with ethyl acetate. The combined organic phase was dried over anhydrous sodium sulfate. The crude product was purified by column chromatography to obtain a light yellow solid I-1 (131.5 mg, yield 65%). 1 H NMR(300MHz, DMSO-d6)δ8.31(s,1H),8.25(d,J=7.8Hz,1H),7.78(s,1H),7.20(s,1H),6.87–6.80(m,2H),6.72–6.67(m,1H),5.65–5 .44(m,3H),4.16(t,J=5.9Hz,2H),3.89(s,3H),3.70–3.55(m,4H),2.71–2.41(m,8H),2.02(t,J=6.1Hz,2H),1.56(d,J=7.1Hz,3H).
[0025] Example 2
[0026]
[0027] Referring to the synthesis method of compound I-1, (R)-3-(1-aminoethyl)-5-(trifluoromethyl)aniline was replaced by (R)-1-[3-(trifluoromethyl)phenyl]ethylamine to obtain compound I-2 (42.6 mg, yield 40%). 1H NMR (300MHz, CDCl3) δ8.51 (s, 1H), 7.73–7.68 (m, 1H), 7.68–7.62 (m, 1H), 7.57–7.50 (m, 1H), 7.46 (dd, J=7.6, 7.5 Hz, 1H), 7.19 (s, 1H), 7.03 (s, 1H), 5.81 (d, J=7.2 Hz ,1H),5.76–5.64(m,1H),4.17(t,J=6.6Hz,2H),3.96(s,3H),3.78–3.70(m,4H),2 .59(t,J=7.1Hz,2H),2.55–2.45(m,4H),2.17–2.04(m,2H),1.72(d,J=6.8Hz,3H).
[0028] Example 3
[0029]
[0030] Referring to the synthesis method of compound I-1, (R)-3-(1-aminoethyl)-5-(trifluoromethyl)aniline was replaced by (R)-3-methyl-phenethylamine to obtain compound I-3 (35.8 mg, yield 65%). 1 H NMR (300MHz, CDCl3) δ8.55(s,1H),7.30–7.25(m,4H),7.19(s,1H),7.15–7.09(m,1H),6.94(s,1H),5.72–5.57(m,2H),4.15(t,J=6.6Hz ,2H),3.97(s,3H),3.78–3.68(m,4H),2.57(t,J=7.1Hz,2H),2.53–2.45(m,4H),2.36(s,3H),2.16–1.99(m,2H),1.69(d,J=6.5Hz,3H).
[0031] Example 4
[0032]
[0033] Referring to the synthesis method of compound I-1, (R)-3-(1-aminoethyl)-5-(trifluoromethyl)aniline was replaced by R-methylbenzylamine to obtain compound I-4 (60.7 mg, yield 70%). 1H NMR(300MHz, CDCl3)δ8.54(s,1H),7.50–7.43(m,2H),7.41–7.33(m,2H),7.33–7.28(m,1H),7.18(s,1H),6.96(s,1H),5.79–5.61(m,2H), 4.13(t,J=6.6Hz,2H),3.96(s,3H),3.77–3.67(m,4H),2.55(t,J=7.1Hz,2H),2.51–2.43(m,4H),2.15–2.02(m,2H),1.70(d,J=6.6Hz,3H).
[0034] Example 5
[0035]
[0036] Referring to the synthesis method of compound I-1, (R)-3-(1-aminoethyl)-5-(trifluoromethyl)aniline was replaced with (R)-1-(3-fluorophenyl)ethylamine to obtain compound I-5 (32.2 mg, yield 36%). 1 H NMR(300MHz, CDCl3)δ8.53(s,1H),7.39–7.11(m,4H),7.04–6.91(m,2H),5.78–5.59(m,2H),4.16(t,J=6.6Hz,2H), 3.97(s,3H),3.82–3.62(m,4H),2.58(t,J=7.0Hz,2H),2.54–2.41(m,4H),2.19–2.05(m,2H),1.69(d,J=6.5Hz,3H).
[0037] Example 6
[0038]
[0039] Referring to the synthesis method of compound I-1, (R)-3-(1-aminoethyl)-5-(trifluoromethyl)aniline is replaced by (αR)-1,1-difluoro-2,3-dihydro-α-methyl-1H-ethylene-4-methylamine to obtain compound I-6 (67.2 mg, yield 73%). 1H NMR (300MHz, CDCl3) δ8.53(s,1H),7.58(d,J=7.5Hz,1H),7.52(d,J=7.4Hz,1 H),7.40(dd,J=7.5,7.4Hz,1H),7.19(s,1H),6.87(s,1H),5.79–5.67(m,1H), 5.44(d,J=7.1Hz,1H),4.17(t,J=6.6Hz,2H),3.77–3.69(m,4H),3.23–3.01( m,2H),2.69–2.54(m,4H),2.53–2.45(m,4H),2.19–2.05(m,2H),1.70(s,3H).
[0040] Example 7
[0041]
[0042] Referring to the synthesis method of compound I-1, (R)-3-(1-aminoethyl)-5-(trifluoromethyl)aniline was replaced with (R)-3-(1-aminoethyl)-2-methylbenzonitrile to obtain compound I-7 (55.1 mg, yield 72%). 1 H NMR (400MHz, CDCl3) δ8.49 (s, 1H), 7.64 (d, J = 7.8Hz, 1H), 7.53 (d, J = 7.5Hz, 1H), 7.26(dd,J=7.8,7.5Hz,1H),7.18(s,1H),6.96(s,1H),5.81–5.70(m,1H),5.62(d ,J=6.3Hz,1H),4.18(t,J=6.5Hz,2H),3.96(s,3H),3.80–3.68(m,4H),2.70(s,3 H),2.59(t,J=7.0Hz,2H),2.50(s,3H),2.17–2.06(m,2H),1.65(d,J=6.8Hz,3H).
[0043] Example 8
[0044]
[0045] Referring to the synthesis method of compound I-1, (R)-3-(1-aminoethyl)-5-(trifluoromethyl)aniline was replaced with (1S)-1-(6-methyl(2-pyridyl))-ethylamine to obtain compound I-8 (20.8 mg, yield 35%). 1H NMR (300MHz, CDCl3) δ8.56(s,1H),7.69–7.52(m,2H),7.24–7.13(m,3H),7.10(d,J=7.9Hz,1H),5.58–5.45(m,1H),4.25(t,J =7.3Hz,2H),3.99(s,3H),3.82–3.65(m,4H),2.69–2.56(m,5H),2.56–2.41(s,4H),2.24–2.09(m,2H),1.64(d,J=6.7Hz,3H).
[0046] Example 9
[0047]
[0048] Referring to the synthesis method of compound I-1, (R)-3-(1-aminoethyl)-5-(trifluoromethyl)aniline was replaced with (1R)-1-(2-methyl(4-pyridyl))-ethylamine to obtain compound I-9 (97.8 mg, yield 32%). 1 H NMR (300MHz, CDCl3) δ8.49(s,1H),8.43(d,J=5.1Hz,1H),7.20(s,2H),7.17–7.12(m,1H),7.11(s,1H),5.91(d,J=6.5Hz,1H),5.64–5.51(m,1 H),4.20(t,J=6.6Hz,2H),3.98(s,3H),3.83–3.70(m,4H),2.64(t,J=7.0Hz,2H),2.60–2.47(m,5H),2.21–2.02(m,4H),1.68(d,J=7.0Hz,3H).
[0049] Example 10
[0050] In vitro SOS1 protein level activity test
[0051] The compounds in the above examples inhibit SOS1 and KRAS G12C The combined activity is tested, and the specific operation is as follows:
[0052] 1. SOS1-KRAS G12C Protein Inhibitory Activity Test Process
[0053] (1) Dissolve the compound to be tested in DMSO to prepare a 10 mM stock solution. Transfer the compound stock solution to the test plate and perform a concentration gradient dilution.
[0054] (2) Prepare Tag1-SOS1 solution with dilution buffer, transfer 5 μL of Tag1-SOS1 solution to the test plate, and add 5 μL of dilution buffer to the low blank control group.
[0055] (3) Prepare Tag2-KRAS with dilution buffer G12C Solution, transfer 5 μL Tag2-KRAS G12C The solution was added to the test plate, and 5 μL of dilution buffer was added to the low blank control group.
[0056] (4) Prepare Anti-Tag1-Tb with detection buffer 3+ and Anti-Tag2-XL665 detection solution. Transfer 10 μL of the detection solution to the detection plate. Place the detection plate in a centrifuge, centrifuge at 1000 rpm for 1 min, and incubate at room temperature for 30 min.
[0057] 2. Data Analysis
[0058] Calculate the ratio of RFU 665nm / RFU 615nm and convert the ratio into a percent inhibition value. Fit the data into Excel to obtain the inhibition value using the following formula:
[0059] Inh%=(Max–Signal) / (Max–Min)×100
[0060] XL-Fit was used to fit the data and the half-inhibitory concentration was obtained using the following formula:
[0061] Y=Bottom+(Top–Bottom) / (1+(IC 50 / X)×HillSlope)
[0062] Y is the inhibition rate and X is the compound concentration.
[0063] 3. Experimental results
[0064] The specific results are shown in the table:
[0065]
[0066]
[0067] Embodiment 11
[0068] In vitro EGFR protein level activity test
[0069] The EGFR enzyme activity of the compounds in the above examples was tested, and the specific operation was as follows:
[0070] 1. EGFR protein inhibitory activity test process
[0071] (1) Dissolve the test compound in DMSO to prepare a 10 mM stock solution. Perform concentration gradient dilution and transfer 5 uL of the test compound solution to the detection plate.
[0072] (2) Prepare kinase solution with dilution buffer, transfer 10 μL of kinase solution to the assay plate, and add 10 μL of dilution buffer to the low blank control group. Incubate at room temperature for 10 minutes.
[0073] (3) Prepare substrate peptide and ATP solution with dilution buffer, transfer 10 μL of substrate peptide and ATP solution to the test plate, and add 10 μL of dilution buffer to the low blank control group. Incubate at 28°C for a period of time, and add 25 μL of reaction stop solution to stop the reaction.
[0074] (4) Add 50 μL of chemiluminescent kinase activity detection reagent and use a multifunctional microplate reader to detect the chemiluminescence value of the system.
[0075] 2. Data Analysis
[0076] The data were fitted into Excel to obtain inhibition values using the following formula:
[0077] Inh%=(Max–Signal) / (Max–Min)×100
[0078] XL-Fit was used to fit the data and the half-inhibitory concentration was obtained using the following formula:
[0079] Y=Bottom+(Top–Bottom) / (1+(IC 50 / X)×HillSlope)
[0080] Y is the inhibition rate and X is the compound concentration.
[0081] 3. Experimental results
[0082] The specific results are shown in the table:
[0083] Compound No. <![CDATA[EGFRIC 50 (nM)]]> Compound No. <![CDATA[EGFRIC 50 (nM)]]> I-1 7855 I-6 11.2 I-2 14.6 I-7 37.5 I-3 8.0 I-8 / 1-4 2.3 I-9 / I-5 2.8
[0084] Example 12
[0085] DLD-1(3D) cell proliferation inhibitory activity test
[0086] 1. Experimental Procedure
[0087] Colon cancer DLD-1 cells with good growth were taken and inoculated into 96-well plates at a density of 500 cells / well, and cultured overnight in a cell culture incubator at 37°C and 5% carbon dioxide. Compounds with gradient dilutions were added, and the cells were cultured in the incubator for 7 days. The detection reagent (Celltiter Glo Assay kit-3D) was added to the 96-well plate (100 μL), and the cells were shaken at room temperature for 5 minutes, incubated at room temperature for 30 minutes in the dark, and then the luminescence value was read using a multifunctional microplate reader.
[0088] 2. Data Analysis
[0089] The percentage inhibition rate can be calculated according to the following formula: inhibition percentage = 100% × (0% inhibition group signal value - signal value at a specific concentration of the test compound) / (0% inhibition group signal value - 100% inhibition group signal value).
[0090] Compound IC 50 The values were fitted using XL-Fit data and calculated using the following formula: Y = Bottom + (Top –
[0091] Bottom) / (1+(IC 50 / X)×HillSlope), Y is the inhibition rate, and X is the concentration of the compound.
[0092] The specific results are shown in the table:
[0093]
[0094]
Claims
1. A quinazoline amine compound as shown in general formula I and a pharmaceutically acceptable salt thereof, the structure of which is as follows: Ar is selected from in, R 1 –R 3 are independently selected from hydrogen, deuterium, halogen, methyl, trifluoromethyl, cyano or amino.
2. A quinazoline amine compound as shown in formula I and a pharmaceutically acceptable salt thereof as claimed in claim 1, characterized in that: The compound shown in formula I is any of the following compounds:
3. A pharmaceutical composition comprising the compound of claims 1 to 2 and a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
4. Use of the quinazoline amine compounds and pharmaceutically acceptable salts thereof according to claims 1 to 2, and the pharmaceutical composition according to claim 3 for preparing SOS1 / EGFR dual-target inhibitors.
5. Use of the quinazoline amine compound or the pharmaceutically acceptable salt thereof according to claims 1 to 2, and the pharmaceutical composition according to claim 3 in the preparation of a drug for preventing or treating cancer.
Citation Information
Patent Citations
EGFR (epidermal growth factor receptor) kinase inhibitor and application thereof in preparation of anti-cancer drugs
CN111909101A
Substituted quinazoline compound, pharmaceutical composition and application of substituted quinazoline compound
CN115141188A
Irreversible inhibitors of tyrosine kinases
CN1218456A
Novel quinazolines and uses thereof
US20030100573A1
Cited By
Ras inhibitors
WO2025240847A1
Methods of treating a ras protein-related disease or disorder
WO2025255438A1
Therapeutic compositions and methods for managing treatment-related effects
WO2025265060A1
Ras inhibitors
WO2026006747A1
Methods of treating a ras related disease or disorder
WO2026015790A1
